290 related articles for article (PubMed ID: 15340577)
21. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
[TBL] [Abstract][Full Text] [Related]
22. [C3d enhances the immune response against HBV-preS2/S following gene immunization in mice].
Guan QD; Wang LX; Guo Q; Zhang JP; Xu W; Wang Y; Xiong SD
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(2):101-5. PubMed ID: 15774215
[TBL] [Abstract][Full Text] [Related]
23. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
24. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
[TBL] [Abstract][Full Text] [Related]
25. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
26. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
27. A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.
Malik IR; Chen A; Brass A; Ahlén G; Rahman M; Sällberg M; Qureshi JA; Frelin L
Scand J Infect Dis; 2012 Jan; 44(1):55-9. PubMed ID: 21933033
[TBL] [Abstract][Full Text] [Related]
28. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
[TBL] [Abstract][Full Text] [Related]
29. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection.
Ren F; Hino K; Yamaguchi Y; Funatsuki K; Hayashi A; Ishiko H; Furutani M; Yamasaki T; Korenaga K; Yamashita S; Konishi T; Okita K
J Med Virol; 2003 Nov; 71(3):376-84. PubMed ID: 12966542
[TBL] [Abstract][Full Text] [Related]
30. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
[TBL] [Abstract][Full Text] [Related]
31. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan.
Mu SC; Lin YM; Jow GM; Chen BF
J Hepatol; 2009 Feb; 50(2):264-72. PubMed ID: 19070923
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
33. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96.
Yan J; Liu X; Wang Y; Jiang X; Liu H; Wang M; Zhu X; Wu M; Tien P
J Gene Med; 2007 Feb; 9(2):107-21. PubMed ID: 17256801
[TBL] [Abstract][Full Text] [Related]
34. Low frequency of precore mutants in anti-hepatitis B e antigen positive subjects with chronic hepatitis B virus infection in Chennai, Southern India.
Shanmugam S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Shankar EM; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
J Microbiol Biotechnol; 2008 Oct; 18(10):1722-8. PubMed ID: 18955826
[TBL] [Abstract][Full Text] [Related]
35. Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines.
Michel M; Lone YC; Centlivre M; Roux P; Wain-Hobson S; Sala M
Vaccine; 2007 Feb; 25(10):1901-11. PubMed ID: 17005303
[TBL] [Abstract][Full Text] [Related]
36. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
Chen X; Li M; Le X; Ma W; Zhou B
Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
[TBL] [Abstract][Full Text] [Related]
37. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
Li X; Yang X; Jiang Y; Liu J
Int Immunol; 2005 Oct; 17(10):1293-302. PubMed ID: 16113237
[TBL] [Abstract][Full Text] [Related]
38. [Reciprocal priming-boosting role of HBsAg and DNA vaccines].
Zhou Z; Chen WS; Zhang HH; Yao JL
Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):212-4. PubMed ID: 12716517
[TBL] [Abstract][Full Text] [Related]
39. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.
Akbar SM; Yoshida O; Chen S; Cesar AJ; Abe M; Matsuura B; Hiasa Y; Onji M
Antivir Ther; 2010; 15(6):887-95. PubMed ID: 20834101
[TBL] [Abstract][Full Text] [Related]
40. Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells.
Ma K; Xu W; Shao X; Yanyue ; Hu L; Xu H; Yuan Z; Zheng X; Xiong S
Antiviral Res; 2007 Nov; 76(2):140-9. PubMed ID: 17655942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
